Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute

Drug Profile

Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute

Latest Information Update: 04 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ChemRegen; Human BioMolecular Research Institute; Sanford Burnham Prebys Medical Discovery Institute
  • Class Cell therapies; Heart failure therapies
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Heart failure

Highest Development Phases

  • Research Heart failure

Most Recent Events

  • 01 Aug 2016 Early research is underway in the US
  • 01 Aug 2016 Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute is available for licensing as of 01 Aug 2016. http://chemregen.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top